1 Hooper DC, Strahilevitz J. Quinolones. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious Diseases. 7th ed: Churchill livingstone Elsievier. p. 487-510.
2 Hernandez A, Sanchez MB, Martinez JL. Quinolone resistance : Much more than Predicted. Frontiers in Microbiology 2011. 2011;2.
3 Torok E, Moran E, cooke F. Global antibiotic use.Oxford handbook of infectious diseases and microbiology. 1st edition ed.
4 Linder J, Huag E, Steinman M, Gonzales R, Stafford R. Fluoroquinolone prescribing in the united states: 1995 to 2002. The American Journal of Medicine. 2005;118:259 to 68.
5 Ohene S-A BM, Ojo J, Toonstra A, Awudi D, Klatser P Extra-pulmonary tuberculosis: A retrospective study of patients in Accra, Ghana. PLoS ONE 2019;14(1).
6 M Ramirez-Lapausa AM-S, A Noguerado-Asensio. Extrapulmonary tuberculosis: an overview. Rev Esp Sanid Penit. 2015;17:3-11.
7 Jacoby G, Cattoir V, Hooper D, Martínez-Martínez L, Nordmann P, Pascual A, et al. qnr gene nomenclature. Antimicrob Agents Chemother. 2008;52:2297-9.
8 Poirel L, Rodriguez-Martinez J, Mammeri H, Liard A, Nordmann P. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob Agents Chemother. 2005;49:3523-5.
9 Jacoby G, Walsh K, Mills D, Walker V, Oh H, Robicsek A, et al. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother. 2006;50:1178-82.
10 Ade S HA, Tre´bucq A, Ade G, Agodokpessi G, et al. National Profile and Treatment Outcomes of Patients with Extrapulmonary Tuberculosis in Be´nin. PLoS ONE. 2014;9(4).
11 Strahilevitzl J, Jacoby G, Hooper DC, Robicsek A. Plasmid-Mediated quinolone resistance : a Multifaceted Threat. American society for Microbiology Clinical Microbiology Reviews. 2009;22:664-89.
12 Jacoby G. Mechanisms of Resistance to Quinolones. Clinical infectious Diseases. 2005;41:S120-S6.
13 Lamikanra A, Crowe JL, Lijek RS, Odetoyin BW, Wain J, Aboderin AO and Okeke IN. Rapid evolution of fluoroquinolone resistant Escherichial coli in Nigeria is temporally asssociated with fluoroquinolone use. BMC infectious diseases. 2011;11:312.
14 Ogbolu DO, Daini OA, Ogunledun A, Alli AO, Webber MA. High Levels of Multidrug Resistance in Clinical Isolates of Gram -Negative pathogens from Nigeria. International Journal of Antimicrobial Agents. 2011;37(1):62-6.
15 Aibinu I, Aednipekun E, Odugbemi T. Emergence of Quinolone Resistance amongst Escherichia coli strains isolated from clinical infections in some Lagos State Hospitals, in Nigeria. Nigeria Journal of Health and Biomedical Sciences. 2004;3:73-8.
16 Ogbolu DO, Alli AO, Anorue MC, Daini OA, Oluwadun A. Distribution of plasmid-mediated quinolone resistance in Gram-negative bacteria froma tertiary hospital in Nigeria. Indian J Pathol Microbiol. 2016;59(3):322-6.
17 Nkemngu N. Susceptibility patterns of Salmonella enterica serovar Typhi to 10 antibiotics in Cameroon. 6th international conference on Typhoid fever and other salmonelloses; Guilin, China2005.
18 Opitan J, Newman M, Nsiah-Poodoh O, Okeke I. Vibrio cholerae 01 from Accra, Ghana carrying a class 2 integron and the SXT element. J Antimicrob Chemother. 2008;62:929-33.
19 Namboodiri S, Opitan J, Lijek R, Newman M, Okeke I. Quinolone resistance in Escherichia coli from Accra, Ghana. BMC Microbiology. 2011;11:44.
20 Aibinu IE, Adenipekun EO, Nwaka DC, Adelowotan AO, Ajekigbe AT, Adeyemi OF, et al. Emmergence of Cross-Resistance to Fluoroquinolones in Gram- Negative isolates from Cancer infections in a Tertiary Hospital in Nigeria. The Journal of American Science. 2008;4(4).
21 Chattaway MA, Aboderin AO, Fashae K, Okoro CK, Opintan JA, Okeke IN. Fluoroquinolone-Resistant Enteric Bacteria in Sub-Saharan African: Clones, Implications and Research Needs. Front Microbiol. 2016;7:558.
22 Mandell G, Bennett J, Dolin R. Urinary tract infections. Mandell, Douglas, and Bennett’s principles and practice of infectious Diseases. Seventh ed: Churchill livingstone Elsievier. p. 971.
23 D.C L. Textbook of Diagnostic Microbiology: Biochemical Identification of Gram-Negative Bacteria. 5 ed: ELSEVIER; 2015.
24 Organization WH. Basic Laboratory Procedures in Clinical Bacteriology. 2 ed. Geneva2003.
25 Institute CaLS. Performance standards for antimicrobial susceptibility testing Wayne, PA; USA: 2009 Contract No.: M100-S19.
26 Bauer A, Kirby W, Sherris J, Turck M. Antibiotic susceptibility testing by a standardized single disk method. . Am J clin Pathol. 1966:493-6.
27 Black JA, Moland ES, Thomson KS. AmpC Disk Test for Detection of Plasmid-Mediated AmpC B-Lactamases in Enterobacteriaceae Lacking Chromosomal AmpC B-Lactamases. J Clin Microbiol. 2005;43(7):3110-3.
28 Ciesielczuk H, Hornsey M, Choi V, Wooford N, Wareham D. Development and evaluation of a multiplex PCR for eight plasmid mediated quinolone resistance determinants. J med Microbiol. 2013;62:1823-7.
29 Ezeh PA, Tende M, Bolaji RO, Olayinka BO, Menegbe BY, Igwe JC. Prevalence of Aac(6')-lb-cr and Qepa Genes among Quinolone Resistant Uropathogens isolated from Asymptomatic female students of a Northern University of Nigeria. Clin Microbiol 2017. 2017;6(5).
30 Albornoz E TN, De Belder D, Gomez S, Martino F, Corso A, Melano R.G., Petroni A,. qnrE1, a Member of a New Family of Plasmid-Located Quinolone Resistance Genes, Originated from the Chromosome of Enterobacter Species. Antimicrobial agents abd Chemotherapy. 2017.
31 Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, et al. Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother. 2008; 61:1003-6.
32 Yang H, Chen H, Yang Q, Chen M, Wang H. High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6′)-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. . Antimicrob Agents Chemother. 2008;52:4268-73.
33 Pai H, Seo M, Choi T. Association of QnrB determinants and production of extended-spectrum β-lactamases or plasmid-mediated AmpC β-lactamases in clinical isolates of Klebsiella pneumoniae. . Antimicrob Agents Chemother. 2007;51:366-8.
34 Szabo D, Kocsis B, Rokusz L, Szentandrassy J, Katona K, Kristof K, et al. First detection of plasmid-mediated, quinolone resistance determinants qnrA, qnrB, qnrS and aac(6′)-Ib-cr in extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in Budapest, Hungary. J Antimicrob Chemother 2008;62:630-2.
35 Gay K, Robicsek A, Strahilevitz J, Park C, Jacoby G, Barrett T, et al. Plasmid mediated quinolone resistance in non-Typhi Salmonella. Clin Infect Dis. 2006;43:297-304.
36 Poirel L, Pitout J, Calvo L, Rodriguez-Martinez J, Church D, Nordmann P. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. . Antimicrob Agents Chemother 2006;50:1525-27.
37 Coque T, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis. 2008.;14:195-200.
38 Robicsek A, Jacoby G, Hooper D. The worldwide emergence of plasmid-mediated qunolone resistance. Lancet infect Dis. 2006;6:629-40.
39 Gourdarzi M, Azad M, Seyedjavadi SS. Prevalence of Plasmid-Mediated Quinolone Resistance Determinants and oqxAB Efflux Pumps among Extended-Spectrum B-Lactamase Producing Klebsiella pneumoniae Isolaed from Patients with Nosocomial Urinary Tract Infections in Tehran, Iran. Scientifica. 2015;7.
40 Morales DR, Slattery, J., Pacurariu, A. et al. Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study. Clin Drug Investig 39, 205–213 (2019). https://doi.org/10.1007/s40261-018-0729-y.